TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia

Doriane Gouas 1, Stéphanie Villar 1,*, Sandra Ortiz-Cuaran 1, Pénélope Legros 1, Gilles Ferro 1, Gregory D. Kirk 2,3, Olufunmilayo A. Lesi 4,5, Maimuna Mendy 1, Ebrima Bah 1,2, Marlin D. Friesen 3, John Groopman 3, Isabelle Chemin 5 and Pierre Hainaut 1,6,*

1International Agency for Research on Cancer, Molecular Carcinogenesis Group, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France, *Gambia Hepatitis Intervention Study, Laboratoires Fajara, Banjul, The Gambia, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA, 4Department of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria and 5Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Hépatocarcinogénèse et infection virale, Lyon, France

*Present address: International Prevention Research Institute, 96 cours Franklin Roosevelt, 69006 Lyon, France
To whom correspondence should be addressed. International Prevention Research Institute, 96 cours Franklin Roosevelt, 69006 Lyon, France. Tel.: +33 4 72 17 11 99; Fax: +33 4 72 17 11 90; Email: pierre.hainaut@i-pri.org

Introductions

Hepatocellular carcinoma (HCC) is a major cause of cancer mortality and morbidity in many parts of the world. Overall, it is the seventh most common cancer globally and the third leading cause of cancer-related deaths (1). Over 80% of HCC occurs in sub-Saharan Africa and Southern and Eastern Asia. In The Gambia, West Africa, incidence rates are 32.84 per 100 000 person-years in men and 14.9 cases per 100 000 in women (2). The main risk factors are chronic hepatitis B virus (HBV), which is endemic in the Gambian population. The proportion of carriers among non-HBV vaccinated Gambians is 15% and aflatoxin B 1 (AFB 1)-contaminated foodstuffs are commonly consumed by >95% of the population (3–5). Other risk factors such as HCV and alcohol are found to play a relatively minor role, particularly in cases arising <50 years of age (4,6). AFB 1 is a mycotoxin produced by the fungus Aspergillus flavus that contaminates the staple diet in many tropical areas, in particular after storage under hot and humid conditions. After ingestion and metabolism in the liver, metabolites of AFB 1 can form a DNA adduct at the third base of codon 249 in the TP53 tumor suppressor gene, inducing a G to T transversion (AGG to AGT, arginine to serine; R249S), a mutation that is detected in >75% of HCC from areas with high AFB 1 exposure (7–10).

Chronic HBV infection is the dominant global attributable risk factor for HCC, accounting for 55% of cases worldwide and >80% in sub-Saharan Africa and South-East Asia (11). The mechanisms by which HBV causes malignant transformation remain uncertain; however, many studies have highlighted a pathogenic role for HBx, the product of the HBV gene HBX, which encodes a 154 amino acid, 17 KDa factor that enhances viral replication and modulates multiple cellular growth signaling pathways (12). One of the molecular hallmarks of HBV-induced HCC is integration of the viral genome into the host cellular genome detected in 80–90% of these cancers (13,14). Integration of viral DNA may lead to insertional mutagenesis (15). In addition, integration often results in a 3’-terminal truncation of HBX, generating a shorter form of the HBX protein that is deleted at the C-terminal region by 20–40 amino acids. Integration is also often accompanied by multiple point mutations in the HBX sequence. In humans, it has been suggested that both truncation and point mutations may enhance the oncogenic activation processes. In experimental models, the C-truncated HBX proteins were shown to transform immortalized liver cell lines (16) and to interact with the mutant p53 protein p.R249S to alter genetic stability and proliferation of non-transformed hepatocytes (17). Other studies found that the mutant p53 protein p.R249S and HBX formed stable complexes in transformed hepatocytes, further suggesting that the two factors could cooperate in hepatocarcinogenesis occurring in a HBV/AFB 1 etiological setting (18).

The genotypes/subgenotypes of HBV show heterogeneity in their global distributions and these strains have differences in their biological properties (19–21). It is now evident that the heterogeneity in this distribution of HBV genotypes/subgenotypes may account not only for differences in the prevalence of HBV mutations in the different populations but may also be responsible for variation in the clinical outcomes of HBV infections and the response to antiviral therapy (22,23).

In this study, we have explored circulating cell-free DNA (CFDNA) from Gambian HCC patients to further address the contribution of R249S and HBX to cancer risk. Previous studies have shown that plasma or serum of cancer subjects (in particular HCC patients) as well as healthy subjects contains detectable amounts of CFDNA (range: 1–500 ng/ml). This CFDNA often contains mutations and epigenetic alterations identical to those detected in tumor tissues (24). In a case–control study of HCC in The Gambia, we have used CFDNA to demonstrate the presence of R249S in up to 40% of HCC patients while low levels of mutant DNA were also detected in non-cancer controls, in particular among high-risk HBV chronic carriers (25,26). Although the molecular mechanisms of release and the stability of CFDNA are still unclear, this resource appears to represent a convenient minimally invasive repository of biomarkers for HCC in regions where liver biopsies are not routinely available. Using CFDNA from the plasma of subjects recruited in a hospital-based case–control study conducted in The Gambia and previously analyzed for R249S status and for HBV serological status, we have examined HBV genotype by sequencing the HBs gene.
(encoding HBsAg) and we have characterized HBX integrity and mutational status.

Materials and methods

Study participants

This study has been conducted using specimens and data from The Gambia Liver Cancer Study, for which design, ethical approval, recruitment procedures and laboratory testing methods have been previously reported (4). Briefly, The Gambia Liver Cancer Study was a hospital-based case–control study in which incident cases of HCC and cirrhosis were recruited from three tertiary hospitals in The Gambia from September 1997 to January 2001. The diagnosis of HCC was based on concordant clinical and ultrasonography findings and on serum levels of α-fetoprotein of ≥ 100 ng/ml. Cirrhosis was diagnosed using clinical parameters and ultrasonography (27). A majority of the cases was confirmed by histopathology of liver biopsies (4). Hospital controls with no clinical evidence for liver disease were frequency matched by age (within 10 years), gender and study site. All study participants provided informed consent and both Gambian and international institutional review boards approved the study protocol.

HBV serology, DNA extraction and quantitation of R249S mutation in CFDNA

Methods and results for HBV serology, DNA extraction and quantitation of R249S mutation in CFDNA have been reported previously (4,25,26). Briefly, HBV surface antigens (HBsAg) and HBV e antigens (HBeAg) were determined as markers of chronic HBV carriage or viral replication, respectively, using standard laboratory kits (Merex Diagnostics Ltd, Dartford, UK and Sorin Biomedica Diagnostics, Vercelli, Italy). CFDNA was extracted from 200 μl of plasma using QiAmp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s blood and body fluid spin protocol. Purified CFDNA was eluted from the QiAmp Silica column with two volumes of water (2 x 50 μl) (PCR-grade, Sigma, St Louis, MO). Quantitation of extracted DNA was performed by fluorometry using picogreen (Molecular Probes, Eugene, OR). R249S was detected using two methods, restriction fragment length polymorphisms (RFLP) (25) or short oligonucleotide mass analysis (SOMA). All samples were analyzed by RFLP and the status of 38% was confirmed by SOMA. The latter method allowed the quantitation of R249S at a synthetic, internal standard as described previously (26) and results were considered as ‘R249S-positive’ at a cutoff number of 67 copies of mutant DNA/ml. Overall, RFLP and SOMA results were highly concordant.

Analysis of HBX truncation status

Detection of truncated versus complete integrated HBX was performed by PCR and sequencing based upon a method initially described by Ma et al. (16) and modified as described previously (28). Briefly, CFDNA was used to produce four overlapping amplimers from HBX gene of 139, 192, 334 or 425 bp. The 425 bp amplicon encompasses the entire HBX sequence and the three shorter amplicons correspond to fragments initiated at the 5’-end of HBX and covering progressively lesser lengths of sequence. Amplification of all four fragments signals the presence of a complete HBX, whereas amplification of one or several shorter fragments signals the presence of 3’-truncated HBX. The same forward primer X1F was used in each reaction (5’-GGGAGACCGCGTG-AAGAGAG-3’), the reverse four primers were XIR1 (5’-GGGAGACCGCGTG-AAGAGAG-3’), XIR2 (5’-GGGAGACCGCGTG-AAGAGAG-3’), XIR3 (5’-GGGAGACCGCGTG-AAGAGAG-3’), or XIR4 (5’-GGGAGACCGCGTG-AAGAGAG-3’). PCR was carried for 50 cycles after activation with GoTaq Hot Star Polymerase at 94°C for 30 s, 60°C for 45 s, and 72°C for 1 min. The second step used 2 μl of the first reaction and primers S HBV123s and S HBVporv2; round setting was 95°C (15 min); 45 cycles of 95°C (30 s), 58°C (30 s), 72°C (1 min); followed by extension at 72°C for 7 min. Five microliters of PCR products were purified using standard ExoSap-IT (Usb Corporation) and both strands were directly sequenced by automated dideoxy sequencing (sequencer AbiPrism 3100; Applied Biosystems) using primers S HBV123s, S HBVporv2 and S HBV778r (5’-GAAGTATAAAGGGACTCAAG-3’). HBV genotypes and subtypes were determined as previously described (31) and phylogenetic trees were built using HBV references from GenBank and the software MEGA5 (29).

Statistical analyses

Odds ratios (ORs), χ² and P values were calculated using STATA 11.1 (College Station, TX). All ORs were adjusted for age and gender.

Results

Characteristics of study participants

In this study, we analyzed a total of 325 controls, 78 patients with cirrhosis and 198 patients with HCC recruited in The Gambia Liver Cancer Study (4). Characteristics of study participants are presented in Table I. Despite frequency matching within 10 years age strata, HCC patients were significantly older than controls and more frequently male than patients with cirrhosis or than controls. HBV chronic carriage (positivity for HBsAg) was significantly more frequent in HCC and in cirrhosis than in controls. HBsAg was detected in 56% (44/78) and in 54% (106/198) of cirrhosis and HCC, respectively; compared with 13% (43/325) of controls [circrhosis: OR 13.36 [95% confidence interval (CI) 1.08–165.04]; HCC: OR 12.19 [95% CI 1.29–115.59)]. Among HBsAg-positive subjects, 32% of cirrhosis and 16% of HCC were HBeAg-positive, compared with 5% of controls [OR for HCC versus controls: 0.77 (95% CI 0.14–4.34); for cirrhosis versus controls: 5.66 (95% CI 1.03–31.06)]. When compared with patients with cirrhosis, patients with HCC were less frequently positive for HBeAg [OR: 0.30 (95% CI 0.12–0.76)]. Median viral loads were higher in cirrhosis and HCC.

Table I. Characteristics of the study participants

<table>
<thead>
<tr>
<th>Clinical status</th>
<th>Controls, n (%)</th>
<th>Cirrhosis, n (%)</th>
<th>HCC, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 30</td>
<td>84 (26)</td>
<td>20 (25.5)</td>
<td>23 (12)</td>
</tr>
<tr>
<td>30–40</td>
<td>62 (19)</td>
<td>17 (22)</td>
<td>36 (18)</td>
</tr>
<tr>
<td>41–50</td>
<td>54 (17)</td>
<td>21 (27)</td>
<td>54 (27)</td>
</tr>
<tr>
<td>≥ 51</td>
<td>125 (38)</td>
<td>20 (25.5)</td>
<td>85 (43)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>224 (69)</td>
<td>50 (64)</td>
<td>160 (81)</td>
</tr>
<tr>
<td>Women</td>
<td>101 (31)</td>
<td>28 (36)</td>
<td>38 (19)</td>
</tr>
<tr>
<td>HBsAg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>43 (13)</td>
<td>44 (56)</td>
<td>106 (54)</td>
</tr>
<tr>
<td>Negative</td>
<td>274 (85)</td>
<td>34 (44)</td>
<td>88 (44)</td>
</tr>
<tr>
<td>N/A</td>
<td>8 (2)</td>
<td>0 (0)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>HBeAg&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>2 (5)</td>
<td>14 (32)</td>
<td>17 (16)</td>
</tr>
<tr>
<td>Negative</td>
<td>39 (90)</td>
<td>27 (61)</td>
<td>87 (82)</td>
</tr>
<tr>
<td>N/A</td>
<td>2 (5)</td>
<td>3 (7)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Viral loads&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 1000 copies/ml&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2.5.10&lt;sup&gt;4&lt;/sup&gt; (22)</td>
<td>9.5.10&lt;sup&gt;6&lt;/sup&gt; (29)</td>
<td>3.4.10&lt;sup&gt;5&lt;/sup&gt; (76)</td>
</tr>
<tr>
<td>&lt; 200, n (%)</td>
<td>21 (49)</td>
<td>15 (34)</td>
<td>30 (28)</td>
</tr>
</tbody>
</table>

N/A: not available.
<sup>a</sup>only for HBsAg-positive subjects.
<sup>b</sup>Median.
Presence of R249S in CFDNA of HCC patients is associated with detection of complete HBx sequence

Integration of HBx in the host cell genome is a hallmark of HCC and this integration often involves truncation of the portion of HBx encoding the C-terminus of the protein. This truncation is thought to somehow activate the oncogenic potential of HBx. Since previous results have shown that the mutant protein pR249S interacts with HBx protein and since this interaction appears to involve the C-terminus of HBx, we reasoned that integration of the complete HBx sequence may occur more frequently in HCC with R249S mutations than in HCC without such R249S mutation. To test this hypothesis, we have analyzed HBx gene status by PCR amplification of four fragments covering overlapping portions of the gene, from the 5'-end to the complete sequence, in the CFDNA of HBV chronic carriers (HBsAg-positive subjects). This strategy allowed to distinguish between absence of HBx sequence (no PCR amplification), presence of truncated HBx (amplification of 1–3 PCR fragments covering regions of progressive length) and presence of complete HBx (amplification of all four PCR fragments, the longer one containing the region encoding the C-terminus).

Table II shows HBx status (undetectable, 3'-truncated or complete) in HBV carriers in relation with detection of R249S mutation in CFDNA. The detection of R249S in these subjects using two methods, RFLP or Soma, has been reported previously (25,26). HBx sequences were detected in 14/43 HBV carrier controls (33%), in 32/44 HBV carrier patients with cirrhosis (73%) and in 89/106 HBV carrier patients with HCC (84%). Among each group, complete HBx sequence was detected in 19% of controls, in 57% of patients with cirrhosis and in 61% patients with HCC. However, when subjects in each group were classified according to R249S status, a clear difference emerged between HCC patients and other groups (Table II). In HCC patients, complete HBx sequences were detected in 43/56 (77%) of R249S+ subjects, as compared with 22/50 (44%) in R249S– subjects. In contrast, the number of HCC patients with truncated HBx was significantly higher among R249S– HCC patients (17/50; 34%) than among R249S+ subjects (7/56, 12%) (test for distribution of R249S+ and R249S– subjects according to HBx status among HCC cases: \( \chi^2 = 12.12; \ p = 0.002 \)). It should be noted, however, that whatever the mutation status, the group of patients with complete HBx is larger than with 3'-truncated HBx (44% versus 34% in R249S-negative patients and 77% versus 12% in R249S-positive patients). Overall, these results suggest that integration of complete HBx sequence is more common in HCC cases with R249S mutation than in cases without this mutation. In the latter cases, 3'-truncation of HBx upon integration appears to be a more common event.

Occult HBV infection based on HBx detection

Although the analysis described above was focused on those subjects identified as HBV carriers solely on the basis of HBsAg status, we investigated whether HBx DNA could be detected among HBsAg-negative subjects as a possible marker of occult HBV infection. Of a total of 396 HBsAg-negative subjects, 34 (9%) were found to harbor HBx sequences in CFDNA (Table III). These 34 subjects included 8/274 controls (3%), 5/34 patients with cirrhosis (15%) and 21/88 (24%) in patients with HCC.

To further assess the significance of HBx sequence detection in HBsAg-negative subjects, we performed a PCR analysis to detect the presence of the HBc gene and correlated it with positivity for anti-HBc antibodies (Table III). Of the 34 HBx-positive subjects, 33 could be analyzed for HBc, among which 29 (85%) were found to be positive for HBC gene or anti-HBc antibodies, thus showing a remarkable correlation between HBx and HBc and anti-HBc antibodies positivity. Overall, these results suggest that detection of HBx sequence is a marker for occult infection and there is a trend toward more frequent occult infection in chronic liver disease and in HCC.

Predominance of HBV genotype E

In previous studies, genotype E was found to be the most common HBV genotype in subjects from The Gambia as well as other parts of West Africa (20,30). In the present study, the HBs gene could be amplified from CFDNA by PCR in 66 of 170 HBx-positive subjects (39%) and sequenced to determine subtypes and establish a phylogenetic tree. Genotype E was detected in 75.5% of these subjects, including 24 controls, 15/19 cirrhosis and 33/43 HCC, with a majority of ayw4 subtype (88%) (Supplementary Table 1, available at Carcinogenesis Online). Twenty-three percent of subjects carried genotype A with 93% of subtype ayw1 and only one subject (1.5%; HCC patient (28)) carried genotype D subtype ayw2. HBx sequences of genotype E were heterogeneously distributed among the existing phylogenetic tree of this genotype, with no relation to disease status (Supplementary Figure 2A, available at Carcinogenesis Online). In contrast, all 15 HBs sequences were distributed into a single group corresponding to subtype ayw2 (Supplementary Figure 2B, available at Carcinogenesis Online). There was no difference in the distribution of genotypes and subgenotypes according to either presence of R249S or clinical status.

HBx sequences and mutations

Since HBs sequences were not available for 104 subjects, we used HBx sequences to identify HBV genotypes. HBx sequences from the 66 subjects genotyped based on HBs sequences were used to establish a phylogenetic tree (Supplementary Figure 3, available at Carcinogenesis Online). This tree separates HBx sequences associated with genotypes A, D or E. By identifying their closest neighbor HBx sequence, it thus became possible to assign HBV genotypes in 76 of the 104 subjects for whom HBs sequences were not available. This analysis further established the presence of genotype E, A and D in 66%, 16.5% and 1% of the subjects, respectively. The remaining 16.5% of HBx sequences could not be clearly classified.

Table III. Number and percentage of subjects according to HBx and HBC in HBsAg-negative subjects

<table>
<thead>
<tr>
<th>Status</th>
<th>HBx, n (%)</th>
<th>HBC, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Complete</td>
<td>3'-truncated</td>
</tr>
<tr>
<td>Control</td>
<td>1 (0.4)</td>
<td>7 (3)</td>
</tr>
<tr>
<td>C (100)</td>
<td>5 (71)</td>
<td>N/A</td>
</tr>
<tr>
<td>Cirrhosis</td>
<td>0 (0)</td>
<td>5 (15)</td>
</tr>
<tr>
<td>N/A</td>
<td>4 (80)</td>
<td>N/A</td>
</tr>
<tr>
<td>HCC</td>
<td>3 (3)</td>
<td>18 (20)</td>
</tr>
<tr>
<td>3 (100)</td>
<td>16 (89)</td>
<td>N/A</td>
</tr>
<tr>
<td>N/A: not applicable.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Positive for anti-HBc antibody or HBC gene, percentages were calculated on HBx-positive subjects.
Further analysis of HBX sequences was performed to identify recurrent point mutations (Figure 1). Three mutation sites were detected in genotypes A and E, including 1753V, the double mutation 1762T/1764A and 1809A. However, the relative frequency of these mutations varied among genotypes (Figure 2). Although 1753V and 1762T/1764A were equally found in both genotypes, 1809A was more common in genotype A than E (75% versus 9%), suggesting a possible genotype-specific effect. An association was observed between the HBV 1762T/1764A double mutations and clinical status. Carriers with this double mutation had an elevated risk of cirrhosis or HCC when compared with carriers without this mutation [cirrhosis: OR: 9.50 (95% CI: 1.50–60.11); HCC: OR: 11.29 (95% CI: 2.07–61.47)]. No significant association was detected between mutations and R249S positivity.

Discussion

In this study, we have used circulating cell-free DNA (CFDNA) from the plasma as a surrogate material to analyze the associations between the status of complete sequences of HBX and the presence of the TP53 mutation R249S in individuals from The Gambia, a country with high incidence of HCC in West Africa. Previous studies have shown that CFDNA in patients with HCC or chronic liver disease was a good source of DNA originating from the liver (24).

Our interpretation is based on the assumption that HBX sequences detected in CFDNA are representative of the integrated status of HBX in hepatocytes. Plasma DNA has proven to be a convenient source to access and analyze liver CFDNA. In previous studies, we have shown that there was an excellent overall concordance between presence of TP53 R249S mutation in the plasma and in HCC tissues of patients from The Gambia (32). This excellent performance of CFDNA as a surrogate for liver DNA provides a convenient approach for studying the molecular pathology of chronic liver disease and HCC in low-resource countries where liver biopsies are not routinely available. Moreover, the use of plasma DNA is well adapted to case–control study designs in which blood samples can be equally obtained from patients and controls. To detect HBX and assess its truncation status in CFDNA, we have adapted a PCR-based method previously described by Ma et al. (16), which generates products of different lengths, the longest one corresponding to full-length HBX sequence. The structure of HBV genome is such that the viral DNA is partially double-stranded, not covalently closed and contains the site of covalent binding of the RNA polymerase in a region overlapping with HBX. This structure precludes the amplification of viral genomes using the PCR approach we have used. Thus, this method preferentially, if not exclusively, detects double-stranded HBX sequences released from liver cells in the bloodstream either in the form of fragmented HBV replication intermediates or in the form of fragments of cellular genomic DNA containing integrated viral sequences. In agreement with this interpretation, we did not observe a higher proportion of complete HBX sequences in patients with the highest viral loads (cirrhosis), which should have been expected if viral genomes were detected.

We have analyzed HBX gene status in the CFDNA of subjects with HCC, cirrhosis or controls (601 samples in total). To our knowledge, this is the first systematic study on HBX genetic status in subjects from West Africa, one of the areas of the world with the highest population carriage of HBV. We found that complete HBX is highly associated with HCC-R249S+ compared with R249S− (P = 0.002), whereas 3’-truncated HBX appears to be more frequent in R249S− HCC, defining an inverse relationship between 3’-truncated HBX and presence of R249S mutation. A study performed in a Chinese population using the same approach has identified 3’-truncated HBX in >70% of HCC cases although it did not examine R249S mutation status (16). Thus, our results suggest that entire HBX is often retained in HCC from this West African population, in particular when the tumor also contains R249S. This observation suggests that HCC in this population may develop according to different mechanism, perhaps corresponding to different mechanism of interplay between the major etiological risk factors, chronic HBV infection and exposure to AFB1. We propose that the association between complete HBX and R249S may reflect a particular mechanism of cooperation between the HBx protein and the mutant p.R249S protein.

Previous studies have shown that the p.R249S mutant protein forms stable complexes with full-length HBx protein (18). It has also been reported that the C-terminus of HBs contains a domain with antiproliferative proapoptotic effects (33). Thus, we propose that interaction between p.R249S and HBx somehow favors the retention and integration of a full-length HBX, perhaps because the mutant protein neutralizes a suppressive activity located in the C-terminus of HBx, thus making its truncation dispensable during hepatocarcinogenesis (Figure 3). This interaction may contribute to explain the strong association between p.R249S and chronic HBV infection in causing HCC. Indeed, presence of p.R249S may bypass the need for generating a truncated HBX product and therefore accelerates hepatocarcinogenesis. Thus, presence of p.R249S may facilitate the maintenance of complete HBX gene until late stages of HCC progression. This
Mutational analysis of HBX identified several common mutation sites in the 3’-end of HBX. The well-studied mutations 1753Y and the double mutation 1762T/1764A were present in >50% and 70% of subjects, respectively, with no difference between genotypes. Among HBV carriers, presence of the double mutation 1762T/1764A was associated with higher risk of cirrhosis or HCC (cirrhosis: OR: 9.50 (95% CI: 1.50–60.11); HCC: OR: 11.29 (95% CI: 2.07–61.47)), consistent with an earlier pilot study in The Gambia (36) and with results in patients from other parts of the world (36–40). The mechanisms by which these mutations enhance the risk of chronic liver disease are still a matter of debate. They may contribute to increase the rate of HBV replication and they may also result into an HBx protein with specific amino acid substitutions enhancing its oncogenic properties (17,41). In contrast with these mutations, the mutation 1809A was more frequently associated with genotype A3 (75%) than genotype E (9%), raising the possibility that this mutation may occur in a genotype-specific manner. Previous studies have shown that at positions 1809–1812 were highly associated with genotype A1 (42,43). These substitutions do not appear to be the result of adaptive changes under immune pressure, since they are also found in HBV isolates obtained from children and in acute hepatitis patients (44,45).

In conclusion, this analysis of HBX status in a case–control study of HCC in The Gambia has shown that there is an association between the presence of complete HBX sequences and the presence of the aflatoxin-induced mutation R249S. The significance of this association for diagnosis, patient prognosis or tumor cell activity needs to be addressed in further studies. Furthermore, this study indicates that occult HBV infection might be present in up to 24% of HCC cases, suggesting that the role of HBV chronicity as attributable risk of HCC in the Gambian population is even greater than previously suggested (46). It will be important to examine how the implementation of neonatal HBV vaccine, which has started in 1986 in the Gambian population, will affect these molecular parameters of HBV infection.

Acknowledgements

G.D.K. has provided consulting to GSK and to Merck regarding hepatitis vaccination.

Conflict of Interest Statement: None declared.

References


Fig. 3. Two hypothetical mechanisms for HBX protein activation in HCC. The protein contains three domains from N- to C-terminal region: an oligomerization domain (OD; aa 21–50); a mitochondria association domain (MT; aa 68–104), which is essential for cell death but not for transactivation function; and a transactivation domain (TAD; aa 132–140). Left: activation by C-truncation (due to integration of 3’-truncated HBX sequence in host genome). Right: activation by neutralization (due to binding of p.R249S to the antiproliferative C-terminal domain of HBX protein encoded by a complete integrated HBX gene).

Supplementary material

Supplementary Table 1 and Figures 1–3 can be found at http://carcin.oxfordjournals.org/.

Funding

This research was supported in part by National Institutes of Health (NIH) grant (P01 ES006052), in part by the National Cancer Institute, NIH, Department of Health and Human Services grant (N02 CP40521), in part by Association pour la Recherche sur le Cancer (ARC-5044) and in part by the American Cancer Society (MRSG-07-284-01-CCE to G.D.K.).

Downloaded from https://academic.oup.com/carcin/article-abstract/33/6/1219/2463623 by guest on 26 January 2019


Received January 3, 2012; revised March 13, 2012; accepted March 17, 2012